CA2111523A1 - Infection control agents - Google Patents
Infection control agentsInfo
- Publication number
- CA2111523A1 CA2111523A1 CA 2111523 CA2111523A CA2111523A1 CA 2111523 A1 CA2111523 A1 CA 2111523A1 CA 2111523 CA2111523 CA 2111523 CA 2111523 A CA2111523 A CA 2111523A CA 2111523 A1 CA2111523 A1 CA 2111523A1
- Authority
- CA
- Canada
- Prior art keywords
- infection control
- particles
- particle size
- control agent
- surface modifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
Abstract
ABSTRACT
The present invention is directed to an infection control composition comprising an aqueous dispersion of particles of at least one infection control agent wherein said particles have a surface modifier adsorbed on the surface thereof in an amount sufficient to achieve a particle size of less than about 400 nanometers (nm). The compositions of the present invention can contain other conventional ingredients.
The present invention is directed to an infection control composition comprising an aqueous dispersion of particles of at least one infection control agent wherein said particles have a surface modifier adsorbed on the surface thereof in an amount sufficient to achieve a particle size of less than about 400 nanometers (nm). The compositions of the present invention can contain other conventional ingredients.
Description
2 ~
INFECTION CONTROL AGENTS
Field of the Invention The present invention relates to infection control agents for use in household and institutional disinfectants, sanitizers, cleaning products, personal care products and hygiene products.
Backqround of the Invention A variety of antimicrobial agents have been formulated into compositions that are marketed as disinfectants, sanitizers, cleaning product~, personal care products and hygiene products. However, many of these agents are poorly soluble in water.
Thus, it is an object of the presen~ invention to increase the dispersibility of these agents in aqueous media while minimizing or eliminating the need for organic solvents.
Summary of the Invention The present invention is directed to an infection control composition that comprises an aqueous dispersion of particles of at least one infection control agent wherein said particles have a surface modifier adsorbed on the surface thereof in an amount sufficient to achieve a particle size of les than about 400 nanometers (nm). The compositions of the present invention can contain other conventional ingredients that are used in such compositions.
Detailed Description of the Invention The compositions of the invention comprise nanoparticles containing infection control agents. The infection control agents can be any of an antimicrobial or other agent such as phenolics, as for example :
-, -,. ~:
' ' ~ ': : ' . :
2 ~
orthophenylphenol or ortho benzyl para chlorophenol, triclosan, thymol, essential oils, parachloro meta xylenol, pyrithiones, aldehydes, analides, carbanilides and iodonium saltsO
The particles of this invention contain a discrete phase of an infection control agent as described above having a surPace modifier adsorbed on the surface thereof. Useful surface modifiers are believed to include those which physically adhere to the surface of the halohydantoin but do not chemically bond to the infection control agent.
Suitable surface modifiers can preferably be selected from known organic and inorganic excipients.
Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants.
Preferred surface modifiers include nonionic and anionic surfactants. Representative examples of excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose hydroxyethylcellulose, hydro~ypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, and polyvinylpyrrolidone (PVP). Most oP these excipients are described in detail in the Handbook of Pharmaceutical Excipients, published jointly ., . - .
:.~. . .
.,,, ~ , . . . . .
~, - . .
, :
- - ' 2 ~
by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986, the disclosure of which is hereby incorporated by reference in its entirety. The surface modifiers are commercially available and/or can be prepared by techniques known in the art.
The surface modifier is adsorbed on the surface of the infection control agent in an amount sufficient to maintain an effective average particle size of less than about 400 nm. The surface modifier does not chemically react with the infection control agent or itself. Furthermore, the individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages.
As used herein, particle size refers to a number average particle size as measured by conventional particle ~ize measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation. By "an effective average particle size of less than about 400 nm" it is meant that at least 90 of the particles have a weight average particle size of less than about 400 nm when measured by the above-noted techniques. In preferred embodiments of the invention, the effective average particle size is less than about 2S0 nm. In some embodiments of the invention, an effective average particle size of less than about 100 nm has been achieved. With reference to the effective average particle size, it is preferred that at least 95%
and, more preferably, at least 99% of the particles have a particle size less than the effective average, e.g., 400 nm. In particularly preferred embodiments, essentially all of the particles have a size less than 400 nm. In some embodiments, essentially all of the particles have a size less than 250 nm.
,~: . ' . . ' : ., . . . ~
,L . , 2 ~ i 2 ~ :
The particles of this invention can be prepared by a method comprising the steps of dispersing an infection control agent in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of the infection control agent to an effective average particle size of less than about 400 Nm. The particles can be reduced in size in the presence of a surface modifier.
Alternatively, the particles can be contacted with a surface modifier after attrition.
These methods are described in detail in U.S.
Patent No. 5,145,684.
The relative amount of infection control agent and surface modifier can vary widely and the optimal amount of the surface modifier can depend, for example, upon the particular infection control agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, etc. The surface modifier preferably is present in an amount of about 0.1-10 mg per square meter surface area of the infection control agent. The surface modifier can be present in an amount of 0.1-99.995%, preferably 20-60~
by weight based on the total weight of the formulation.
The infection control agent nanoparticles of the present invention can be incorporated into conventional disinfectant, detergent or germicide compositions, as for example those disclosed in u.S.
Patent Nos. 3,824,190 and 3,944,498, the disclosures of which is incorporated herein.
The compositions of the present invention can be illustrated by the following representative example.
.i ~
. ~ ~
: ,, l;
~ - `
Exam~le 1 Disinfectant Cleaner Concentrate Wt. %
Soap/Surfactant 4.5 Nanoparticle Antimicrobial (Phenolic) 7.8 Solvent 10.0 Builders 0.5 Fragrances 0.2 Dye 0.001 Water 76 - 78 The foregoing specification, including the specific embodiments and example is intended to be illustrative of the present invention and is not to be taken as limiting. Numerous other variations and modifications can be effected without departing from the true spirit and scope of the present invention~
, ~ ' ' .
INFECTION CONTROL AGENTS
Field of the Invention The present invention relates to infection control agents for use in household and institutional disinfectants, sanitizers, cleaning products, personal care products and hygiene products.
Backqround of the Invention A variety of antimicrobial agents have been formulated into compositions that are marketed as disinfectants, sanitizers, cleaning product~, personal care products and hygiene products. However, many of these agents are poorly soluble in water.
Thus, it is an object of the presen~ invention to increase the dispersibility of these agents in aqueous media while minimizing or eliminating the need for organic solvents.
Summary of the Invention The present invention is directed to an infection control composition that comprises an aqueous dispersion of particles of at least one infection control agent wherein said particles have a surface modifier adsorbed on the surface thereof in an amount sufficient to achieve a particle size of les than about 400 nanometers (nm). The compositions of the present invention can contain other conventional ingredients that are used in such compositions.
Detailed Description of the Invention The compositions of the invention comprise nanoparticles containing infection control agents. The infection control agents can be any of an antimicrobial or other agent such as phenolics, as for example :
-, -,. ~:
' ' ~ ': : ' . :
2 ~
orthophenylphenol or ortho benzyl para chlorophenol, triclosan, thymol, essential oils, parachloro meta xylenol, pyrithiones, aldehydes, analides, carbanilides and iodonium saltsO
The particles of this invention contain a discrete phase of an infection control agent as described above having a surPace modifier adsorbed on the surface thereof. Useful surface modifiers are believed to include those which physically adhere to the surface of the halohydantoin but do not chemically bond to the infection control agent.
Suitable surface modifiers can preferably be selected from known organic and inorganic excipients.
Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants.
Preferred surface modifiers include nonionic and anionic surfactants. Representative examples of excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose hydroxyethylcellulose, hydro~ypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, and polyvinylpyrrolidone (PVP). Most oP these excipients are described in detail in the Handbook of Pharmaceutical Excipients, published jointly ., . - .
:.~. . .
.,,, ~ , . . . . .
~, - . .
, :
- - ' 2 ~
by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986, the disclosure of which is hereby incorporated by reference in its entirety. The surface modifiers are commercially available and/or can be prepared by techniques known in the art.
The surface modifier is adsorbed on the surface of the infection control agent in an amount sufficient to maintain an effective average particle size of less than about 400 nm. The surface modifier does not chemically react with the infection control agent or itself. Furthermore, the individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages.
As used herein, particle size refers to a number average particle size as measured by conventional particle ~ize measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation. By "an effective average particle size of less than about 400 nm" it is meant that at least 90 of the particles have a weight average particle size of less than about 400 nm when measured by the above-noted techniques. In preferred embodiments of the invention, the effective average particle size is less than about 2S0 nm. In some embodiments of the invention, an effective average particle size of less than about 100 nm has been achieved. With reference to the effective average particle size, it is preferred that at least 95%
and, more preferably, at least 99% of the particles have a particle size less than the effective average, e.g., 400 nm. In particularly preferred embodiments, essentially all of the particles have a size less than 400 nm. In some embodiments, essentially all of the particles have a size less than 250 nm.
,~: . ' . . ' : ., . . . ~
,L . , 2 ~ i 2 ~ :
The particles of this invention can be prepared by a method comprising the steps of dispersing an infection control agent in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of the infection control agent to an effective average particle size of less than about 400 Nm. The particles can be reduced in size in the presence of a surface modifier.
Alternatively, the particles can be contacted with a surface modifier after attrition.
These methods are described in detail in U.S.
Patent No. 5,145,684.
The relative amount of infection control agent and surface modifier can vary widely and the optimal amount of the surface modifier can depend, for example, upon the particular infection control agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, etc. The surface modifier preferably is present in an amount of about 0.1-10 mg per square meter surface area of the infection control agent. The surface modifier can be present in an amount of 0.1-99.995%, preferably 20-60~
by weight based on the total weight of the formulation.
The infection control agent nanoparticles of the present invention can be incorporated into conventional disinfectant, detergent or germicide compositions, as for example those disclosed in u.S.
Patent Nos. 3,824,190 and 3,944,498, the disclosures of which is incorporated herein.
The compositions of the present invention can be illustrated by the following representative example.
.i ~
. ~ ~
: ,, l;
~ - `
Exam~le 1 Disinfectant Cleaner Concentrate Wt. %
Soap/Surfactant 4.5 Nanoparticle Antimicrobial (Phenolic) 7.8 Solvent 10.0 Builders 0.5 Fragrances 0.2 Dye 0.001 Water 76 - 78 The foregoing specification, including the specific embodiments and example is intended to be illustrative of the present invention and is not to be taken as limiting. Numerous other variations and modifications can be effected without departing from the true spirit and scope of the present invention~
, ~ ' ' .
Claims
1. An infection control composition comprising an aqueous dispersion of particles of at least one infection control agent wherein said particles have a surface modifier adsorbed on the surface thereof in an amount sufficient to achieve a particle size of less than about 400 nanometers (nm), a surfactant, a dye and a fragrance.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99133192A | 1992-12-16 | 1992-12-16 | |
US07/991,331 | 1992-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2111523A1 true CA2111523A1 (en) | 1994-06-17 |
Family
ID=25537112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2111523 Abandoned CA2111523A1 (en) | 1992-12-16 | 1993-12-15 | Infection control agents |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2111523A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016194A1 (en) * | 1996-10-11 | 1998-04-23 | Quest International B.V. | Perfumed products |
WO2000013656A1 (en) * | 1998-09-04 | 2000-03-16 | Kay Chemical Company | Antimicrobial composition for handwash and a method of cleaning skin using the same |
WO2000066070A2 (en) * | 1999-04-30 | 2000-11-09 | Henkel Kommanditgesellschaft Auf Aktien | Utilization of nanoscalar, antimicrobial active ingredients in oral and/or dental hygiene |
CN1063610C (en) * | 1996-02-06 | 2001-03-28 | 天津市医药工业技术研究所 | Broad-spectrum fungicide |
WO2001075213A1 (en) * | 2000-04-04 | 2001-10-11 | Henkel Kommanditgesellschaft Auf Aktien | Use of 3-iodine-2-propinyl-carbamates as antimicrobial active agent |
US6716438B1 (en) | 1999-04-30 | 2004-04-06 | Cognis Deutschland Gmbh & Co. Kg | Use of nanoscalar antimicrobial active ingredients in body deodorants |
-
1993
- 1993-12-15 CA CA 2111523 patent/CA2111523A1/en not_active Abandoned
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1063610C (en) * | 1996-02-06 | 2001-03-28 | 天津市医药工业技术研究所 | Broad-spectrum fungicide |
WO1998016194A1 (en) * | 1996-10-11 | 1998-04-23 | Quest International B.V. | Perfumed products |
AU728959B2 (en) * | 1996-10-11 | 2001-01-25 | Quest International B.V. | Perfumed products |
US6241979B1 (en) | 1996-10-11 | 2001-06-05 | Quest International B.V. | Perfumed products containing a mixture of perfume materials having antibacterial properties |
WO2000013656A1 (en) * | 1998-09-04 | 2000-03-16 | Kay Chemical Company | Antimicrobial composition for handwash and a method of cleaning skin using the same |
WO2000066070A2 (en) * | 1999-04-30 | 2000-11-09 | Henkel Kommanditgesellschaft Auf Aktien | Utilization of nanoscalar, antimicrobial active ingredients in oral and/or dental hygiene |
WO2000066070A3 (en) * | 1999-04-30 | 2001-04-05 | Henkel Kgaa | Utilization of nanoscalar, antimicrobial active ingredients in oral and/or dental hygiene |
US6716438B1 (en) | 1999-04-30 | 2004-04-06 | Cognis Deutschland Gmbh & Co. Kg | Use of nanoscalar antimicrobial active ingredients in body deodorants |
WO2001075213A1 (en) * | 2000-04-04 | 2001-10-11 | Henkel Kommanditgesellschaft Auf Aktien | Use of 3-iodine-2-propinyl-carbamates as antimicrobial active agent |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5256328A (en) | Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles | |
US5354564A (en) | Personal care compositions | |
US3956480A (en) | Treatment of teeth | |
JP4653073B2 (en) | Controlled release composition | |
CA2491670A1 (en) | Compositions having enhanced deposition of a topically active compound on a surface | |
JPH05339138A (en) | Use of alpha-hydroxy fatty acid and composition containing the same | |
CA2179740A1 (en) | Oat oil compositions with useful dermatological properties | |
JP2001518944A (en) | Antibacterial, mild rinse-off liquid cleaning composition containing acidic surfactant | |
KR20110081198A (en) | An antimicrobial composition | |
EP1450759A2 (en) | Waterless hand cleaner containing natural essential oil | |
EP0306236A2 (en) | Controlled release formulations | |
US5145685A (en) | Skin treatment method and composition | |
CN108130225B (en) | Cleaning composition, cleaning agent, and preparation method and application thereof | |
JP2002504114A (en) | Antibacterial, mild rinse-off liquid cleaning composition | |
EP3558002B1 (en) | An antimicrobial composition comprising oligodynamic metal | |
CA2111523A1 (en) | Infection control agents | |
MXPA06013337A (en) | Syndet bars having ultraviolet radiation protection. | |
WO1997020867A1 (en) | Powdery complexes of hydrogen peroxide and polymers | |
WO2017045893A1 (en) | Release of odoriferous substances from microcapsules | |
JP4892220B2 (en) | Oral composition | |
AU616044B2 (en) | Cleansing composition for topical disinfection | |
CN112449600A (en) | Composition for preventing adhesion of fine particles in air | |
CA2111526A1 (en) | Miticide compositions | |
JP2010024366A (en) | Cleanser | |
DE102016219296A1 (en) | Perfume-containing enamel body |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |